References
1. Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.2017;14(2):284-297.
2. Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Seminars in cancer biology.2018;51:50-58.
3. Grimm SA, Chamberlain MC. Brainstem glioma: a review. Current neurology and neuroscience reports. 2013;13(5):346.
4. Mackay A, Burford A, Carvalho D, et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer cell. 2017;32(4):520-537.e525.
5. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.Nature genetics. 2014;46(5):444-450.
6. Sturm D, Pfister SM, Jones DTW. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(21):2370-2377.
7. Gwak HS, Park HJ. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Critical reviews in oncology/hematology. 2017;120:111-119.
8. Khan DA, Laghari AA, Bari ME, Shamim MS. Treatment options for paediatric brainstem gliomas. JPMA The Journal of the Pakistan Medical Association. 2019;69(9):1400-1402.
9. Chi AS, Tarapore RS, Hall MD, et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Journal of neuro-oncology. 2019;145(1):97-105.
10. Larson JD, Kasper LH, Paugh BS, et al. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. Cancer cell. 2019;35(1):140-155.e147.
11. Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for Outcomes Research: A Review. JAMA oncology.2017;3(12):1722-1728.
12. Doll KM, Rademaker A, Sosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database.JAMA surgery. 2018;153(6):588-589.
13. Zhao YY, Wan QS, Hao Z, Zhu HX, Xing ZL, Li MH. Clinical nomogram for predicting the survival of patients with cerebral anaplastic gliomas. Medicine. 2020;99(10):e19416.
14. Donovan LE, Lassman AB. Chemotherapy Treatment and Trials in Low-Grade Gliomas. Neurosurgery clinics of North America.2019;30(1):103-109.
15. Espinoza JC, Haley K, Patel N, et al. Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials.Pediatric blood & cancer. 2016;63(10):1806-1813.
16. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. The Lancet Oncology.2015;16(4):e173-180.
17. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.2008;26(8):1364-1370.
18. Liang W, Zhang L, Jiang G, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.2015;33(8):861-869.
19. Zhang G, Wu B, Wang X, Li J. A competing-risks nomogram and recursive partitioning analysis for cause-specific mortality in patients with esophageal neuroendocrine carcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2019;32(11).
20. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.2018;36(19):1963-1972.
21. Zhao YY, Chen SH, Hao Z, Zhu HX, Xing ZL, Li MH. A Nomogram for Predicting Individual Prognosis of Patients with Low-Grade Glioma.World neurosurgery. 2019;130:e605-e612.
22. Yang T, Mao P, Chen X, et al. Inflammatory biomarkers in prognostic analysis for patients with glioma and the establishment of a nomogram.Oncology letters. 2019;17(2):2516-2522.
23. Chen H, Judkins J, Thomas C, et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017;88(19):1805-1813.
24. Picca A, Berzero G, Di Stefano AL, Sanson M. The clinical use of IDH1 and IDH2 mutations in gliomas. Expert review of molecular diagnostics. 2018;18(12):1041-1051.
25. Zhou L, Wang Z, Hu C, et al. Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation. Journal of proteome research. 2019;18(3):960-969.
26. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. The New England journal of medicine. 2015;372(26):2499-2508.